Drug Trial Radar · NCT06072183
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,571
Actual
Start
Nov 8, 2023
Primary completion
Jul 30, 2027
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental vitiligo. Vitiligo causes white patches on your skin when the cells that give your skin color are destroyed. Nonsegmental means that it can affect both sides of the body such as both knees and both hands. Ritlecitinib has been tested in earlier clinical studies and has a favorable safety profile. At present there are no approved medications taken by mouth to treat nonsegmental vitiligo. This study is seeking participants who: * Are 18 years of age or older. * are confirmed to have nonsegmental vitiligo for at least 3 months. * Are willing to stop all other treatments that they may be taking for vitiligo. In this study participants will be chosen by chance, like drawing names out of a hat to receive 1 of 3 treatments: •Part I where two different amounts of ritlecitinib (50 mg and 100 mg) are taken once daily. It will be compared to placebo. Placebo is a dummy capsule. It doesn't have any medicine used in the study. Participants receiving placebo who have not responded to treatment after 52 weeks will be given 100 milligrams or 50 milligrams of ritlecitinib for the remaining 52 weeks of the study. • In Part II, participants will only receive 100 milligrams of ritlecitinib. About 1000 participants will take part in Part I and around 450 in Part II globally. The study will compare the experiences of people receiving ritlecitinib to those of the people who do not. This will help see if ritlecitinib is safe and effective. People in Part I will be in this study for about 26 months and people in Part II will be in this study for about 14 months. During the study, participants in part I will need to visit the study site at least 17 times. In part II, participants will visit at least 11 times. Participants will undergo various tests and procedures such as: * vitiligo rating, * physical examinations, * hearing tests, * blood tests, * x-ray, * ECG, * photographs of areas with vitiligo. Participants will be asked to complete questionnaires about their vitiligo.
Conditions
- Stable Nonsegmental Vitiligo
- Active Nonsegmental Vitiligo
Interventions
RitlecitinibDrug
100mg Capsule
RitlecitinibDrug
50mg Capsule
PlaceboDrug
Matching capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and Total body Vitiligo Area Scoring Index 50 (T-VASI50) at Week 52Time frame: 52 Weeks
- Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52Time frame: 52 Weeks
- Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) leading to discontinuation.Time frame: Baseline through 108 weeks
- Incidence of Clinically significant laboratory abnormalities.Time frame: Baseline through 108 weeks
Locations
229 sites in 18 countries. Site status is shown where the registry gives one.
Center for Dermatology and Plastic Surgery/CCT Research
Scottsdale, Arizona
Dermatology Trial Associates
Bryant, Arkansas
First OC Dermatology Research Inc
Fountain Valley, California
Seaside Audiology Vertigo & Ear Specialists
Huntington Beach, California
Wallace Medical Group, Inc
Los Angeles, California
Kaiser Permanente
Oakland, California
Cura Clinical Research - Oxnard
Oxnard, California
Mission Dermatology Center
Rancho Santa Margarita, California
Peninsula Research Associates
Rolling Hills Estates, California
Integrative Skin Science and Research
Sacramento, California
University of California San Diego - La Jolla
San Diego, California
Wolverine Clinical Trials
Santa Ana, California
Encore Medical Research of Boynton Beach
Boynton Beach, Florida
FXM Clinical Research - Fort Lauderdale
Fort Lauderdale, Florida
Direct Helpers Research Center
Hialeah, Florida
Clever Medical Research
Miami, Florida
Miami Dermatology and Laser Research
Miami, Florida
SouthCoast Research Center
Miami, Florida
University of Miami Dermatology Clinical Trials Unit
Miami, Florida
University of Miami
Miami, Florida
Bio-Medical Research LLC
Miami, Florida
New Horizon Research Center
Miami, Florida
Skin Research of South Florida
Miami, Florida
Well Pharma Medical Research, Corp.
Miami, Florida
FXM Clinical Research - Miami
Miami, Florida
Health and Life Research Institute
Miami, Florida
University of Miami, Kendall Office
Miami, Florida
Floridian Research Institute Llc
Miami, Florida
Sanitas Research
Miami, Florida
Wellness Clinical Research, LLC
Miami Lakes, Florida
FXM Clinical Research Miramar, LLC
Miramar, Florida
GCP Research, Global Clinical professionals
St. Petersburg, Florida
Advanced Clinical Research Institute
Tampa, Florida
USF Health
Tampa, Florida
Sidney P. Smith, MD, PC dba Georgia Skin & Cancer Clinic
Savannah, Georgia
Endeavor Health Audiology -CHICAGO
Chicago, Illinois
Endeavor Health Audiology -LAKE BLUFF
Lake Bluff, Illinois
Endeavor Health Audiology-NORTHBROOK
Northbrook, Illinois
Endeavor Health Audiology-SKOKIE
Skokie, Illinois
Endeavor Health-Dermatology Clinical Trials Unit
Skokie, Illinois
Showing 40 of 229 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.